Abstract
The progress of clinical gene therapy trials during the last two decades has been remarkable, and its application has also expanded into various fields of human diseases. Among them, hereditary diseases such as the primary immunodeficiency diseases (PID) were considered suitable candidates for gene therapy because the therapeutic strategy was very simple, therefore, effective gene therapy may be obtained without significant difficulty compared to other more complex diseases such as cancer. Indeed, the first clinical gene therapy trial was safely performed and was in part, effective for adenosine deaminase (ADA) deficiency patients, a type of severe combined immunodeficiency diseases (SCID). However, because of certain unforeseen obstacles, it took approximately 10 years until the first curative effects were obtained for gene therapy in patients with X-linked SCID (X-SCID). Here, I review and discuss the background and historical events leading up to PID gene therapy, the safety issues, which unexpectedly arose after the successful report, and finally I will attempt to predict the future trends in this form of gene therapy.
Keywords: adenosine deaminase, severe combined immunodeficiency disease (SCID), LMO2 gene, Vector insertion, leukocyte adhesion deficiency (LAD)
Current Pharmaceutical Design
Title: Gene Therapy for Primary Immunodeficiency Diseases: Recent Progress and Misgivings
Volume: 12 Issue: 5
Author(s): Tadashi Ariga
Affiliation:
Keywords: adenosine deaminase, severe combined immunodeficiency disease (SCID), LMO2 gene, Vector insertion, leukocyte adhesion deficiency (LAD)
Abstract: The progress of clinical gene therapy trials during the last two decades has been remarkable, and its application has also expanded into various fields of human diseases. Among them, hereditary diseases such as the primary immunodeficiency diseases (PID) were considered suitable candidates for gene therapy because the therapeutic strategy was very simple, therefore, effective gene therapy may be obtained without significant difficulty compared to other more complex diseases such as cancer. Indeed, the first clinical gene therapy trial was safely performed and was in part, effective for adenosine deaminase (ADA) deficiency patients, a type of severe combined immunodeficiency diseases (SCID). However, because of certain unforeseen obstacles, it took approximately 10 years until the first curative effects were obtained for gene therapy in patients with X-linked SCID (X-SCID). Here, I review and discuss the background and historical events leading up to PID gene therapy, the safety issues, which unexpectedly arose after the successful report, and finally I will attempt to predict the future trends in this form of gene therapy.
Export Options
About this article
Cite this article as:
Ariga Tadashi, Gene Therapy for Primary Immunodeficiency Diseases: Recent Progress and Misgivings, Current Pharmaceutical Design 2006; 12 (5) . https://dx.doi.org/10.2174/138161206775474378
DOI https://dx.doi.org/10.2174/138161206775474378 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medical Management of Obesity
Current Nutrition & Food Science The Cough Receptor TRPV1 Agonists 15(S)-HETE and LTB4 in the Cough Response to Hypertonicity
Inflammation & Allergy - Drug Targets (Discontinued) Design and Development of Anti-Hepatitis B Virus Agents
Current Medicinal Chemistry The Pathogenic Role of Persistent Milk Signaling in mTORC1- and Milk- MicroRNA-Driven Type 2 Diabetes Mellitus
Current Diabetes Reviews Recent Patents on Thiazole Derivatives Endowed with Antitumor Activity
Recent Patents on Anti-Cancer Drug Discovery Crosstalk between Gut Microbiota and Central Nervous System: A Focus on Alzheimer's Disease
Current Alzheimer Research Circulatory Estrogen Level Protects Against Breast Cancer in Obese Women
Recent Patents on Anti-Cancer Drug Discovery ABC Transporters in Extrahepatic Tissues: Pharmacological Regulation in Heart and Intestine
Current Medicinal Chemistry Editorial [Hot topic:Food Addiction & Obesity Treatment Development (Executive Guest Editors: Mark S. Gold and Noni A. Graham)]
Current Pharmaceutical Design Assessment and Management of the Adnexal Mass in the Pediatric Population
Current Women`s Health Reviews Regulation of Iron Absorption in Hemoglobinopathies
Current Molecular Medicine New Trends in Biological Activities and Clinical Studies of Quinolinic Analogues: A Review
Current Drug Targets Epigenetics and the Environmental Regulation of the Brain's Genome and its Function
Current Psychiatry Reviews Recent Advances in Iron-Catalyzed C-H Bond Activation Reactions
Current Inorganic Chemistry (Discontinued) HR-MAS NMR Spectroscopy: A Practical Guide for Natural Samples
Current Organic Chemistry Multicolor-FISH Approaches for the Characterization of Human Chromosomes in Clinical Genetics and Tumor Cytogenetics
Current Genomics Obesity in China: What are the Causes?
Current Pharmaceutical Design Targeting Neurotrophic Signal Transduction Pathways in the Treatment of Mood Disorders
Current Signal Transduction Therapy Epidermolysis Bullosa: The Pediatricians Role
Current Pediatric Reviews Sex Steroid Hormone Effects in Normal and Pathologic Conditions in Lung Physiology
Mini-Reviews in Medicinal Chemistry